V. Buffard

736 citations
11 papers · 471 indexed · 1 hit paper · h-index 5

V. Buffard

9 papers receiving 454 citations

Hit Papers

Phase II Study of Cetuximab As First-Line Single-Drug The...3342011202620162021100200300

Peers

V. Buffard
Comparison fields: 5 of 42
  • Dermatology 194
  • Epidemiology 297
  • Oncology 204
  • Rheumatology 75
  • Immunology 100
Replace Amel Mebazâa with:
Amel Mebazâa Tunisia
Anne-Bénédicte Duval-Modeste France
Osama Roshdy Canada
Maria Estela Martínez‐Escala United States
Karen Rebecca Suchin United States
Michael Krathen United States
Pedram Geraminejad United States
Ziba Rahbar Iran
M. Vogelbruch Germany
John D. Hendrix United States
V. Buffard relative to Amel Mebazâa Tunisia Amel Mebazâa's profile →
Citations per field
00.5×1.5×2.5×
Amel Mebazâa · 1×
Citations per year

Countries citing papers authored by V. Buffard

Since Specialization
Citations

This map shows the geographic impact of V. Buffard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Buffard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Buffard more than expected).

Fields of papers citing papers by V. Buffard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Buffard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Buffard. The network helps show where V. Buffard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside V. Buffard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with V. Buffard Line = papers co-authored together V. Buffard links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1 201522
2 201510
3 20131
4 20123
5
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skinbreakdown →
2011334
6 20113
7 20107
8
Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
200789
9 20061
10 20050
11 20041

About V. Buffard

V. Buffard is a scholar working on Rheumatology, Neurology and Pharmacology, having authored 11 papers that have together received 471 indexed citations. Recurring topics across this work include Drug-Induced Adverse Reactions (3 papers), Urticaria and Related Conditions (2 papers), Neurofibromatosis and Schwannoma Cases (2 papers), Autoimmune Neurological Disorders and Treatments (1 paper), Immunodeficiency and Autoimmune Disorders (1 paper), Autoimmune Bullous Skin Diseases (1 paper), Soft tissue tumor case studies (1 paper) and Protein Tyrosine Phosphatases (1 paper). The work is most often cited by research in Dermatology (194 citations), Epidemiology (297 citations) and Oncology (204 citations). V. Buffard has collaborated with scholars based in France and United States. Frequent co-authors include Xavier Duval, H. Adamski, Ludovic Lacroix, Sandrine Mansard, A. Dompmartin, Florent Grange, Peter Petrow, Marie‐Françoise Avril, B. Crickx and France Mentré. Their work appears in journals such as Dermatology, Journal of Clinical Oncology, Journal of Pediatric Orthopaedics, Journal of the European Academy of Dermatology and Venereology and Annales de Dermatologie et de Vénéréologie.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026